The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Open accessAbstract
The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Zhang, X., He, X., Liu, Y., Zhang, H., Chen, H., Guo, S., & Liang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.005 · Cited by 97
RetractedLiu, D., Zhu, Y., Pang, J., Weng, X., Feng, X., & Guo, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26297 · Cited by 66
RetractedLuan, W., Li, R., Liu, L., Ni, X., Shi, Y., Xia, Y. F., Wang, J., Lu, F., & Xu, B. (2017) · Oncotarget · doi:10.18632/oncotarget.19910 · Cited by 63
RetractedHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
PI3K signalling in inflammation
Hawkins, P. T., & Stephens, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.006 · Cited by 541
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Genetic heterogeneity of diffuse large B-cell lymphoma
Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A., Dunphy, C., Choi, W., Au, W. Y., Srivastava, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205299110 · Cited by 527
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., Cheresh, D. A., & Johnson, R. S. (2008) · Nature · doi:10.1038/nature07445 · Cited by 471
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Yip, C. K., Murata, K., Walz, T., Sabatini, D. M., & Kang, S. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.017 · Cited by 372
Ghia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., de la Serna, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03355 · Cited by 372
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 369
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 341
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., Nassif, N. T., & McGowan, E. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0803-3 · Cited by 312
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib
Rao, V. K., Webster, S., Dalm, V. A. S. H., Šedivá, A., van Hagen, P. M., Holland, S., Rosenzweig, S. D., Christ, A. D., Sloth, B., Cabanski, M., et al. (2017) · Blood · doi:10.1182/blood-2017-08-801191 · Cited by 290
Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function
Papa, A., Wan, L., Bonora, M., Salmena, L., Song, M. S., Hobbs, R. M., Lunardi, A., Webster, K., Ng, C., Newton, R. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.027 · Cited by 276
Alpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
Toska, E., Osmanbeyoglu, H. U., Castel, P., Chan, C., Hendrickson, R. C., Elkabets, M., Dickler, M. N., Scaltriti, M., Leslie, C. S., Armstrong, S. A., et al. (2017) · Science · doi:10.1126/science.aah6893 · Cited by 265
Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx289 · Cited by 265
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Hanker, A. B., Kaklamani, V., & Arteaga, C. L. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1175 · Cited by 251
Zelenetz, A. D., Barrientos, J. C., Brown, J. R., Coiffier, B., Delgado, J., Egyed, M., Ghia, P., Illés, Á., Jurczak, W., Marlton, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30671-4 · Cited by 250
Juric, D., Janku, F., Rodón, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 246
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires-Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 240
Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 238
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
Zhang, X., Xie, K., Zhou, H., Wu, Y., Li, C., Liu, Y., Liu, Z., Xu, Q., Liu, S., Xiao, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01171-z · Cited by 237
PI3Kγ inhibition: towards an 'aspirin of the 21st century'?
Rückle, T., Schwarz, M. K., & Rommel, C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2145 · Cited by 232
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
Jiang, Y., Jiang, Y.-Y., Xie, J.-J., Mayakonda, A., Hazawa, M., Chen, L., Xiao, J.-F., Li, C.-Q., Huang, M.-L., Ding, L.-W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06081-9 · Cited by 227
Yang, Q., Modi, P., Newcomb, T., Quéva, C., & Gandhi, V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2034 · Cited by 222
Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., Kannan, S., Verma, C. S., Dickler, M., Chandarlapaty, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.004 · Cited by 222
Venkatesan, A. M., Dehnhardt, C. M., Delos Santos, E., Chen, Z., Dos Santos, O., Ayral-Kaloustian, S., Khafizova, G., Brooijmans, N., Mallon, R., Hollander, I., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901830p · Cited by 216
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214
Huang, J.-L., Cao, S.-W., Ou, Q.-S., Yang, B., Zheng, S.-H., Tang, J., Chen, J., Hu, Y.-W., Zheng, L., & Wang, Q. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0841-x · Cited by 214
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Ellis, B. C., Graham, L. D., & Molloy, P. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.10.016 · Cited by 210
Flinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., Wagner-Johnston, N. D., Coutre, S. E., Benson, D. M., Peterman, S., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538546 · Cited by 210
Burris, H. A., Flinn, I. W., Patel, M. R., Fenske, T. S., Deng, C., Brander, D. M., Gutierrez, M., Essell, J. H., Kuhn, J. G., Miskin, H. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30082-2 · Cited by 205
Costa, C., Ebi, H., Martini, M., Beausoleil, S. A., Faber, A. C., Jakubik, C. T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.007 · Cited by 203
Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy
Kong, D., & Yamori, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00891.x · Cited by 184
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Yang, N., Chen, J., Zhang, H., Wang, X., Yao, H., Peng, Y., & Zhang, W. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.358 · Cited by 179
Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., Van den Abbeele, A. D., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 177
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
Simpson, D. R., Mell, L. K., & Cohen, E. E. W. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.012 · Cited by 169
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer, C., Sturge, J., Bennett, D. C., O’Hare, M. J., Allen, W. E., Bain, J., Jones, G. E., & Vanhaesebroeck, B. (2003) · PubMed · Cited by 169
Wen, P. Y., Touat, M., Alexander, B. M., Mellinghoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01207 · Cited by 169
Yan, J., Dang, Y., Liu, S., Zhang, Y., & Zhang, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-5448-5 · Cited by 168
Dbouk, H. A., Vadas, O., Shymanets, A., Burke, J. E., Salamon, R. S., Khalil, B. D., Barrett, M. O., Waldo, G. L., Surve, C. R., Hsueh, C., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2003264 · Cited by 166
Cheng, C., Qin, Y., Zhi, Q., Wang, J., & Qin, C. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.10.154 · Cited by 166
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini Rocco, E., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020) · Genes · doi:10.3390/genes11070719 · Cited by 166
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 162
Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1080 · Cited by 162
Copanlisib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0838-6 · Cited by 162
Targeting PI3 kinase in cancer
Bauer, T. M., Patel, M. R., & Infante, J. R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.006 · Cited by 160
Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Poznak, C. H. V., Storniolo, A. M., Nangia, J. R., Ericsson, P. I. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2170 · Cited by 160
Lin, A., Piao, H.-L., Li, Z., Sarbassov, D. D., Ma, L., & Gan, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1729 · Cited by 159
Ke, J., Yao, Y.-L., Zheng, J., Wang, P., Liu, Y.-H., Ma, J., Li, Z., Liu, X.-B., Li, Z.-Q., Wang, Z.-H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4290 · Cited by 158
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 154
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 152
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Gasser, J. A., Inuzuka, H., Lau, A. W., Wei, W., Beroukhim, R., & Toker, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.023 · Cited by 149
Duvelisib: First Global Approval
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-1013-4 · Cited by 149
Zhu, Y. T., Zhang, X., Qi, L., Cai, Y., Yang, P., Xuan, G., & Jiang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7418 · Cited by 148
Garrido-Castro, A. C., Saura, C., Barroso‐Sousa, R., Guo, H., Ciruelos, E., Bermejo, B., Gavilá, J., Serra, V., Prat, A., Paré, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01354-y · Cited by 147
Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 143
Powles, T. B., Lackner, M. R., Oudard, S. M., Escudier, B. J., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8808 · Cited by 141
Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 138
Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138
Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 137
Doukas, J., Wrasidlo, W., Noronha, G., Dneprovskaia, E., Fine, R., Weis, S. M., Hood, J. D., DeMaria, A. N., Söll, R., & Cheresh, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606956103 · Cited by 132
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer
Elmenier, F. M., Lasheen, D. S., & Abouzid, K. A. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111718 · Cited by 127
Foster, J. G., Blunt, M. D., Carter, E. P., & Ward, S. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004051 · Cited by 123
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120
Wang, Y., Kuramitsu, Y., Baron, B., Kitagawa, T., Tokuda, K., Akada, J. K., Maehara, S., Maehara, Y., & Nakamura, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3804 · Cited by 120
Davids, M. S., Kim, H. T., Nicotra, A., Savell, A., Francoeur, K., Hellman, J. M., Bazemore, J., Miskin, H. P., Sportelli, P., Stampleman, L. V., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30196-0 · Cited by 117
Song, L., Zhou, Z., Gan, Y., Li, P., Xu, Y., Zhang, Z., Luo, F., Xu, J., Zhou, Q., & Dai, F. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28244 · Cited by 115
Münster, P. N., Aggarwal, R. R., Hong, D. S., Schellens, J. H. M., van der Noll, R., Specht, J. M., Witteveen, P. O., Werner, T. L., Dees, E. C., Bergsland, E. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1665 · Cited by 114
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G. B., Rutherford, P., Gallegos, A. C., Massey, K. L., & Powis, G. (1995) · PubMed · Cited by 113
Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function
Fung‐Leung, W. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.002 · Cited by 112
Molinaro, A., Becattini, B., Mazzoli, A., Bleve, A., Radici, L., Maxvall, I., Sopasakis, V. R., Molinaro, A., Bäckhed, F., & Solinas, G. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.010 · Cited by 109
Tanaka, H., Yoshida, M., Tanimura, H., Fujii, T., Sakata, K., Tachibana, Y., Ohwada, J., Ebiike, H., Kuramoto, S., Morita, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2882 · Cited by 108
Jiang, W., He, T., Liu, S., Zheng, Y., Xiang, L., Pei, X., Wang, Z., & Yang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0674-5 · Cited by 108
Structural comparisons of class I phosphoinositide 3-kinases
Amzel, L. M., Huang, C., Mandelker, D. L., Lengauer, C., Gabelli, S. B., & Vogelstein, B. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2443 · Cited by 107
Pan, H., Jiang, T., Cheng, N., Wang, Q., Ren, S., Li, X., Zhao, C., Zhang, L., Cai, W., & Zhou, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10521 · Cited by 107
Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P. G., Ballestrero, A., Dubsky, P. C., Lombard, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30334-1 · Cited by 107
Wen, P. Y., Cloughesy, T. F., Olivero, A. G., Morrissey, K. M., Wilson, T. R., Lu, X., Mueller, L. U., Coimbra, A. F., Ellingson, B. M., Gerstner, E. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2808 · Cited by 107
Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
Yacqub‐Usman, K., Pickard, M. R., & Williams, G. T. (2015) · The Prostate · doi:10.1002/pros.22952 · Cited by 105
Kong, D., & Yamori, T. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.150 · Cited by 105
The Network of Non-coding RNAs in Cancer Drug Resistance
Corrà, F., Agnoletto, C., Minotti, L., Baldassari, F., & Volinia, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00327 · Cited by 104
Juric, D., Bono, J. S. D., LoRusso, P. M., Nemunaitis, J. J., Heath, E. I., Kwak, E. L., Macarulla, T. M., Geuna, E., Miguel, M. J. D., Patel, C. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2888 · Cited by 103
Loibl, S., de la Peña, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C., Rezai, M., Bermejo, B., Untch, M., Lee, S. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.020 · Cited by 103
Bendell, J. C., Kurkjian, C. D., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., Shih, K. C., Thompson, D. S., Lane, C. M., Finney, L. H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0218-6 · Cited by 101
Tsai, K., Lo, Y.-H., Liu, H., Yeh, C.-Y., Chen, Y.-Z., Hsu, C.-W., Chen, W.-S., & Wang, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0821-1 · Cited by 101
Mayer, I. A., Prat, A., Egle, D., Blau, S. H., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M. A., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 100
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 99
Tabernero, J. M., van Geel, R. M. J. M., Guren, T. K., Yaeger, R. D., Spreafico, A., Faris, J. E., Yoshino, T., Yamada, Y., Kim, T. W., Bendell, J. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3544 · Cited by 99
Schmid, P., Pinder, S. E., Wheatley, D. A., Macaskill, J., Zammit, C., Hu, J. J., Price, R., Bundred, N. J., Hadad, S. M., Shia, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9179 · Cited by 97
Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0322-4 · Cited by 96
Wen, P. Y., Omuro, A. M. P., Ahluwalia, M. S., Fathallah‐Shaykh, H. M., Mohile, N. A., Lager, J. J., Laird, A., Tang, J., Jiang, J., Égile, C., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov083 · Cited by 94
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Rodrigues, D. A., Sagrillo, F. S., & Fraga, C. A. M. (2019) · Pharmaceuticals · doi:10.3390/ph12020069 · Cited by 94
Makker, V., Recio, F. O., Ma, L., Matulonis, U. A., Lauchle, J., Parmar, H. R., Gilbert, H., Ware, J. A., Zhu, R., Lu, S., et al. (2016) · Cancer · doi:10.1002/cncr.30286 · Cited by 93
Schöffski, P., Cresta, S., Mayer, I. A., Wildiers, H. P. M. W., Damian, S., Gendreau, S. B., Rooney, I. A., Morrissey, K. M., Spoerke, J. M., Ng, V., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1015-x · Cited by 93
Fox, E. M., Kuba, M. G., Miller, T. W., Davies, B. R., & Arteaga, C. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3449 · Cited by 92
Massard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Cheah, C. Y., Nastoupil, L. J., Neelapu, S. S., Forbes, S. G., Oki, Y., & Fowler, N. H. (2015) · Blood · doi:10.1182/blood-2015-03-633156 · Cited by 89
Bardia, A., Gounder, M. M., Rodon, J. A., Jankú, F., Lolkema, M. P., Stephenson, J., Bedard, P. L., Schüler, M., Sessa, C., LoRusso, P. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0297 · Cited by 89
The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity
Aoki, M., Schetter, C., Himly, M., Batista, O., Chang, H. W., & Vogt, P. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6267 · Cited by 88
Ando, Y., Inada‐Inoue, M., Mitsuma, A., Yoshino, T., Ohtsu, A., Suenaga, N., Sato, M., Kakizume, T., Robson, M., Quadt, C., et al. (2014) · Cancer Science · doi:10.1111/cas.12350 · Cited by 88
Langer, C. J., Redman, M. W., Wade, J. L., Aggarwal, C., Bradley, J. D., Crawford, J., Stella, P. J., Knapp, M. H., Miao, J., Minichiello, K., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.029 · Cited by 88
Sharma, P., Abramson, V. G., O’Dea, A. P., Nye, L. E., Mayer, I. A., Pathak, H. B., Hoffmann, M. S., Stecklein, S. R., Elia, M., Lewis, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4879 · Cited by 86
Fazio, N., Buzzoni, R., Baudin, É., Antonuzzo, L., Hubner, R. A., Lahner, H., de Herder, W. W., Raderer, M., Teulé, À., Capdevila, J., et al. (2016) · PubMed · Cited by 85
Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
Meseure, D., Vacher, S., Lallemand, F., Alsibai, K. D., Hatem, R., Chemlali, W., Nicolas, A., de Koning, L., Pasmant, É., Callens, C., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.123 · Cited by 85
Wang, H., Li, Q., Tang, S., Li, M., Feng, A., Qin, L., Liu, Z., & Wang, X. (2016) · Hematology · doi:10.1080/10245332.2016.1258152 · Cited by 83
Smith, S. M., Pitcher, B. N., Jung, S., Bartlett, N. L., Wagner‐Johnston, N. D., Park, S. I., Richards, K. L., Cashen, A. F., Jaslowski, A. J., Smith, S. E., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30028-5 · Cited by 82
Westhoff, M., Kandenwein, J. A., Karl, S., Vellanki, S. H., Braun, V., Eramo, A., Antoniadis, G., Debatin, K., & Fulda, S. (2009) · Oncogene · doi:10.1038/onc.2009.215 · Cited by 79
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway
Sun, K., Wu, D., Chen, S., Zhao, Y., & Zong, Z. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1426-7 · Cited by 79
Yuan, W., Stawiski, E. W., Janakiraman, V., Chan, E., Durinck, S., Edgar, K. A., Kljavin, N. M., Rivers, C. S., Gnad, F., Roose‐Girma, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.53 · Cited by 78
Lu, Y., Li, Y., Chai, X., Kang, Q., Zhao, P., Xiong, J., & Wang, J. (2017) · Gene · doi:10.1016/j.gene.2017.01.004 · Cited by 77
Huen, A., Haverkos, B. M., Zain, J. M., Ramchandren, R., Lechowicz, M. J., Devata, S., Korman, N. J., Pinter‐Brown, L. C., Oki, Y., Barde, P. J., et al. (2020) · Cancers · doi:10.3390/cancers12082293 · Cited by 74
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
Ohwada, J., Ebiike, H., Kawada, H., Tsukazaki, M., Nakamura, M., Miyazaki, T., Morikami, K., Yoshinari, K., Yoshida, M., Kondoh, O., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.065 · Cited by 73
Heudel, P., Fabbro, M., Roemer-Bécuwe, C., Kaminsky, M., Arnaud, A., Joly, F., Roche-Forestier, S., Meunier, J., Foa, C., You, B., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.430 · Cited by 72
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., Aasebø, E., Hernandez-Valladares, M., Hagen, K. M., Rye, K. P., Berven, F. S., Selheim, F., Reikvam, H., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0050-0 · Cited by 71
Dunn, L. A., Riaz, N., Fury, M. G., McBride, S. M., Michel, L. S., Lee, N. Y., Sherman, E. J., Baxi, S. S., Haque, S. S., Katabi, N., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.09.050 · Cited by 71
Nastoupil, L. J., Lunning, M. A., Vose, J. M., Schreeder, M. T., Siddiqi, T., Flowers, C. R., Cohen, J. B., Burger, J. A., Wierda, W. G., O'Brien, S. M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30216-3 · Cited by 70
Liu, M., Zhang, Q., Yuan, X., Jin, L., Wang, L., Fang, T., & Wang, W. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i9.1004 · Cited by 69
Brown, J. R., Hamadani, M., Hayslip, J. W., Janssens, A. M., Wagner‐Johnston, N. D., Ottmann, O. G., Arnason, J. E., Tilly, H., Millenson, M. M., Offner, F. C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30030-9 · Cited by 69
WICKI, A. N., Brown, N. F., Xyrafas, A., Bize, V., Hawle, H., Berardi, S., Cmiljanović, N., Cmiljanović, V., Stumm, M., Dimitrijević, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.012 · Cited by 68
Song, C., Bae, Y., Jun, J., Lee, H., Kim, N. D., Lee, K., Hur, W., Park, J., & Sim, T. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.034 · Cited by 67
André, F., Ciruelos, E. M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.010 · Cited by 67
Wang, Y., Kuang, H., Xue, J., Liao, L., Yin, F., & Zhou, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.024 · Cited by 66
Zhang, Y., Xiang, C., Wang, Y., Duan, Y., Liu, C., Jin, Y., & Zhang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.120 · Cited by 61
Danilov, A. V., Herbaux, C., Walter, H. S., Hillmen, P., Rule, S. A., Kio, E. A., Karlin, L., Dyer, M. J. S., Mitra, S. S., Yi, P. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3504 · Cited by 61
Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors
Clement, E., Inuzuka, H., Nihira, N. T., Wei, W., & Toker, A. (2018) · Science Signaling · doi:10.1126/scisignal.aao3810 · Cited by 60
Tolaney, S. M., Burris, H. A., Gartner, E. M., Mayer, I. A., Saura, C., Maurer, M., Ciruelos, E., García, A. A., Campana, F., Wu, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3248-4 · Cited by 59
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., & McCubrey, J. A. (2010) · Cancers · doi:10.3390/cancers2031576 · Cited by 59
Vera, A. A. D., Gupta, P., Lei, Z., Liao, D., Narayanan, S., Teng, Q., Reznik, S. E., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.020 · Cited by 59
Foster, P., Yamaguchi, K., Hsu, P. P., Qian, F., Du, X., Wu, J., Won, K.-A., Yu, P., Jaeger, C. T., Zhang, W., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0833 · Cited by 58
A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
Yang, S., Xiao, X., Meng, X., & Leslie, K. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026343 · Cited by 57
Hotte, S. J., Chi, K. N., Joshua, A. M., Tu, D., Macfarlane, R. J., Gregg, R. W., Ruether, J. D., Basappa, N. S., Finch, D. L., Salim, M., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.005 · Cited by 57
Ramanathan, R. K., Hoff, D. D. V., Eskens, F. A. L. M., Blumenschein, G. R., Richards, D., Genvresse, I., Reschke, S., Granvil, C. P., Skubala, A., Peña, C. E., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00714-0 · Cited by 57
Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 55
Juric, D., Soria, J., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade‐Potelleret, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9051 · Cited by 55
Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Dbouk, H. A., Khalil, B. D., Wu, H., Shymanets, A., Nürnberg, B., & Backer, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063833 · Cited by 54
Frazzetto, M., Suphioglu, C., Zhu, J., Schmidt‐Kittler, O., Jennings, I. G., Cranmer, S. L., Jackson, S. P., Kinzler, K. W., Vogelstein, B., & Thompson, P. E. (2008) · Biochemical Journal · doi:10.1042/bj20080512 · Cited by 54
Wu, J., Cheng, G., Zhang, C., Zheng, Y., Xu, H., Yang, H., & Hua, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s129928 · Cited by 54
Ragon, B. K., Kantarjian, H. M., Jabbour, E. J., Ravandi, F., Cortes, J. E., Borthakur, G. M., Debose, L., Zeng, Z., Schneider, H., Pemmaraju, N., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24568 · Cited by 53
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Walsh, K. J., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., Smith, J., Beaven, A., Jima, D. D., & Davé, S. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1060 · Cited by 52
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
Song, J. H., Singh, N., Luevano, L. A., Padi, S. K. R., Okumura, K., Olive, V., Black, S. M., Warfel, N. A., Goodrich, D. W., & Kraft, A. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0374 · Cited by 52
Rodon, J. A., Curigliano, G., Delord, J., Harb, W. A., Azaro, A., Han, Y., Wilke, C., Donnet, V., Sellami, D. B., & Beck, T. (2018) · Oncotarget · doi:10.18632/oncotarget.25854 · Cited by 51
Ando, Y., Iwasa, S., Takahashi, S., Saka, H., Kakizume, T., Natsume, K., Suenaga, N., Quadt, C., & Yamada, Y. (2018) · Cancer Science · doi:10.1111/cas.13923 · Cited by 51
Liu, X., Xiong, H., Huang, J., Qi, K., & Xu, J. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12780 · Cited by 50
Wang, W., Lim, K. G., Feng, M., Bao, Y., Lee, P. L., Cai, Y., Chen, Y., Zhang, H., Marzese, D. M., Hoon, D. S. �., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0802 · Cited by 50
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 49
Gopal, A. K., Fanale, M. A., Moskowitz, C. H., Shustov, A. R., Mitra, S. S., Ye, W., Younes, A., & Moskowitz, A. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx028 · Cited by 49
Hill, K. M., Kalifa, S., Das, J., Bhatti, T., Gay, M. D., Williams, D., Taliferro-Smith, L., & Marzo, A. D. D. (2010) · The Prostate · doi:10.1002/pros.21108 · Cited by 47
Makinoshima, H., Umemura, S., Suzuki, A., Nakanishi, H., Maruyama, A., Udagawa, H., Mimaki, S., Matsumoto, S., Niho, S., Ishii, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2109 · Cited by 47
Blagden, S. P., Olmin, A., Josephs, D. H., Stavraka, C., Zivi, A., Pinato, D. J., Anthoney, A., Decordova, S., Swales, K. E., Riisnaes, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1315 · Cited by 46
Liao, Z., Zhao, J. L., & Yang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8782 · Cited by 45
Zhan, M., Deng, Y., Zhao, L., Yan, G., Wang, F., Tian, Y., Zhang, L., Jiang, H., & Chen, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00357 · Cited by 44
Cited by
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 280
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Metadata
- Authors
- Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-27
- Volume
- 22
- Issue
- 7
- Pages
- 3464
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3141987310
- Cited by
- 281
- References
- 257
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.